Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer

Table 1

Summery of the literature on nedaplatin-based concurrent chemoradiotherapy.

Author (Reference)	Year	Study type	Setting	Stage	Results
J. Kodama [19]	2008	Phase I	Postoperative RT	Ib-IIb	Weekly 35 mg/m^2 of nedaplatin was recommended.
Y. Kobayashi [21]	2009	Retro	Postoperative RT	Ib2-IIb	Biweekly 70 mg/m^2 of nedaplatin was employed. CCRT was better than RT alone, but the improvement was not significant.
S. Mabuchi [20]	2009	Retro	Postoperative RT	IA2-IIb	Weekly 40 mg/m^2 of nedaplatin was employed.; CCRT was significantly better than RT alone.
Y. Onishi [14]	2002	Phase I	Definitive RT	III-IVa	Weekly 30 mg/m^2 of nedaplatin was recommended.
K. Yoshinaga [15]	2007	Phase I	Definitive RT	Ib2-IIIb	Weekly 35 mg/m^2 of nedaplatin was recommended.
Y. Yokoyama [16]	2008	Phase II	Definitive RT	Ib2-IVa	Weekly 30 mg/m^2 of nedaplatin was employed.
Y. Niibe [17]	2008	Phase II	Definitive RT	IIIa-IVa	Weekly 30 mg/m^2 of nedaplatin was employed.
S. Mabuchi [18]	2010	Retro	Definitive RT	IIIb	Weekly 35mg/m^2 of nedaplatin was employed.; CCRT was significantly better than RT alone.

CCRT: concurrent chemoradiotherapy, Retro: retrospective cohort study, RT: radiotherapy.